New combo therapy aims to shrink hard-to-treat head and neck tumors
Disease control
Recruiting now
This early-phase study tests a new drug (RiMO-301) combined with targeted radiation and an immunotherapy drug (PD-1 inhibitor) in people with advanced head and neck cancer that cannot be removed by surgery. The goal is to find a safe dose and see if the treatment can shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC